Breaking News

iVexSol Closes $23.8M Series A-3 Financing Deal

The new funding will be used to invest in iVexSol’s Intelligent Vector Solutions by advancing process and analytical technologies.

iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. Investors Bristol Myers Squibb, Charles River Laboratories, and Asahi Kasei Medical, a division of Asahi Kasei, join existing investors including: Casdin Capital and BioLife Solutions to close Series A financing at a total of more than $39 million. The new funding will be used to invest in iVexSol’s Intelligent Vector Solutions ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters